Synthesis, Antimicrobial Evaluation, and Computational Study of Novel Fluorinated Benzofuran Derivatives

Objective: A series of novel fluorine containing ( Z )-5-chloro-2-(4-fluorobenzylidene)-4,6-dimethylbenzofuran-3(2 H )-one ( IVa–IVe ) and ( E )-(5-chloro-3-(4-fluorostyryl)-4,6-dimethylbenzofuran-2-yl)(4-chlorophenyl)methanone derivatives ( Va–Ve ) have been synthesized by using ( E )-1-(3-chloro-6...

Full description

Saved in:
Bibliographic Details
Published in:Russian journal of bioorganic chemistry 2024-10, Vol.50 (5), p.1710-1723
Main Authors: Dengale, S. G., Deshmukh, K. K., Akolkar, H. N., Darekar, N. R., Shaikh, M. H., Khedkar, V. M., Kasar, S. D.
Format: Article
Language:English
Subjects:
Affinity
Binding
Biochemistry
Biomedical and Life Sciences
Biomedicine
Bioorganic Chemistry
Chemical synthesis
Fluorine
Life Sciences
Molecular docking
NMR
Nuclear magnetic resonance
Organic Chemistry
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: A series of novel fluorine containing ( Z )-5-chloro-2-(4-fluorobenzylidene)-4,6-dimethylbenzofuran-3(2 H )-one ( IVa–IVe ) and ( E )-(5-chloro-3-(4-fluorostyryl)-4,6-dimethylbenzofuran-2-yl)(4-chlorophenyl)methanone derivatives ( Va–Ve ) have been synthesized by using ( E )-1-(3-chloro-6-hydroxy-2,4-dimethylphenyl)-3-(4-fluorophenyl)prop-2-en-1-one ( IIIa–IIIe ). Methods: The formation of the synthesized compounds was confirmed by IR, 1 H, 13 C NMR, and mass spectral data. All synthesized compounds were screened for their antimicrobial activity. Results and Discussion: Most of the synthesized compounds have shown better antimicrobial activity as compared to standard drug. Molecular docking study against DNA gyrase could provide insights into binding modes and affinities. The binding affinity data was found to be in harmony with the experimental antimicrobial activities. Conclusions: Furthermore, analysis of the drug-like properties produced good results qualifying these leads as oral drug candidates.
ISSN:1068-1620
1608-330X
DOI:10.1134/S1068162024050194